Vivo Capital’s Dyne Therapeutics DYN Stock Holding History

Vivo Capital’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.6M	Hold	1,557,466	–	–	3.16%	12
2026 Q1	$28.2M	Sell	1,557,466 -1,057,494	-40%	-$18.2M	2.35%	13
2025 Q4	$51.1M	Hold	2,614,960	–	–	3.31%	8
2025 Q3	$33.1M	Buy	2,614,960 +1,500,000	+135%	+$17.1M	2.66%	12
2025 Q2	$10.6M	Hold	1,114,960	–	–	1.09%	16
2025 Q1	$11.7M	Hold	1,114,960	–	–	1.54%	10
2024 Q4	$26.3M	Hold	1,114,960	–	–	2.94%	6
2024 Q3	$40M	Sell	1,114,960 -520,176	-32%	-$20.7M	3.31%	8
2024 Q2	$57.7M	Hold	1,635,136	–	–	5.33%	5
2024 Q1	$46.4M	Buy	1,635,136 +600,000	+58%	+$13.6M	3.65%	8
2023 Q4	$13.8M	Hold	1,035,136	–	–	1.13%	17
2023 Q3	$9.27M	Buy	1,035,136 +457,494	+79%	+$4.93M	1.02%	25
2023 Q2	$6.5M	Hold	577,642	–	–	0.45%	31
2023 Q1	$6.65M	Hold	577,642	–	–	0.46%	28
2022 Q4	$6.7M	Hold	577,642	–	–	0.77%	28
2022 Q3	$7.34M	Hold	577,642	–	–	0.81%	32
2022 Q2	$3.97M	Hold	577,642	–	–	0.4%	42
2022 Q1	$5.57M	Hold	577,642	–	–	0.38%	42
2021 Q4	$6.87M	Hold	577,642	–	–	0.41%	42
2021 Q3	$9.38M	Hold	577,642	–	–	0.42%	40
2021 Q2	$12.2M	Hold	577,642	–	–	0.53%	35
2021 Q1	$8.97M	Buy	577,642 +262,642	+83%	+$5.08M	0.32%	45
2020 Q4	$6.62M	Hold	315,000	–	–	0.3%	47
2020 Q3	$6.36M	Buy	+315,000	New	+$6.91M	0.37%	48

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vivo Capital's DYN Position: Q2 2026 in Review

Vivo Capital held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 1,557,466 shares worth $34.6M. The position accounts for 3.16% of the portfolio, ranked #12.

Vivo Capital first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $57.7M in Q2 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Vivo Capital held 1,557,466 shares of Dyne Therapeutics worth $34.6M as of Q2 2026.
Vivo Capital left its Dyne Therapeutics share count unchanged in Q2 2026.
Dyne Therapeutics made up 3.16% of Vivo Capital's portfolio in Q2 2026, its #12 holding.
Vivo Capital first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
Vivo Capital's Dyne Therapeutics position peaked at $57.7M in Q2 2024.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.